



NEWS RELEASE

## eidos therapeutics to present at 36th annual j.p. morgan healthcare conference

2018-01-05

SAN FRANCISCO, Jan. 5, 2018 /PRNewswire/ -- **Eidos Therapeutics**, a clinical stage biopharmaceutical company, today announced that Neil Kumar, Ph.D., the company's chief executive officer, will present a company overview at the 36<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Tuesday, January 9<sup>th</sup> at 4:00-4:25 p.m. PST in San Francisco, CA.

Eidos is developing AG10, a novel small molecule therapeutic for the treatment of transthyretin amyloidosis. AG10 is currently being evaluated in a Phase 1 clinical trial in healthy volunteers.

### About transthyretin amyloidosis

Transthyretin (TTR) amyloidosis (ATTR) is a progressive, fatal disease caused by the accumulation of misfolded TTR in multiple organ systems. Mutations in TTR destabilize the protein and predispose individuals to developing ATTR, though the disease can also develop in older individuals without genetic mutations. Misfolded TTR is toxic to cells, and aggregated amyloid fibers can cause further organ dysfunction.

Over 250,000 people worldwide suffer from ATTR. However, the prevalence may be underestimated due to its rarity (driving lack of awareness) and confusion with more common diseases (driving misdiagnosis and/or delayed diagnosis). Most patients are properly diagnosed after age 60, when the disease is already advanced, and may progress rapidly thereafter.

There are no FDA-approved medications indicated for the treatment of TTR amyloidosis.

## About AG10

AG10 is a small molecule that selectively and potently binds to and stabilizes TTR, preventing its dissociation into disease-causing monomers. AG10 was discovered and initially developed by Eidos' co-founders Isabella Graef, MD, and Mamoun Alhamadsheh, PhD, at Stanford University and the University of the Pacific, respectively.

## About Eidos Therapeutics

Eidos Therapeutics is a clinical stage biopharmaceutical company based in San Francisco. Eidos is developing AG10 as precision medicine for transthyretin amyloidosis. The company's singular mission is to improve the lives of patients suffering from this disease. Launched in 2016 after years of research supported by Stanford's TRAM and SPARK programs, Eidos is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe, effective treatment to market as quickly as possible.

SOURCE Eidos Therapeutics

## Related Links

<http://www.eidostx.com>